UNCATEGORIZED
Enteric coating oral peptide research has emerged as a critical discipline within preclinical pharmacology, addressing the fundamental challenge that gastric acid destroys the majority of biologically active peptide sequences before they can reach intestinal absorption sites. pH-responsive polymer coatings — including Eudragit L100, hydroxypropyl methylcellulose phthalate (HPMC-P), cellulose acetate phthalate (CAP), and shellac — form the technical foundation of modern oral peptide delivery systems studied in controlled laboratory settings.
Peptides are amino acid chains connected by labile amide bonds. In the gastric environment — where pH ranges from approximately 1.5 to 3.5 and pepsin activity is high — these bonds are cleaved rapidly, rendering the peptide biologically inactive. Research published in the Journal of Controlled Release (Lakkireddy et al., 2016) demonstrated that unprotected peptide analogs lose more than 80% of their structural integrity within 30 minutes of exposure to simulated gastric fluid (SGF, pH 1.2, USP).
Enteric coatings circumvent this degradation by forming a barrier that remains intact at low (gastric) pH and dissolves only when the formulation reaches the higher pH environment of the small intestine. This pH-triggered dissolution is not a passive effect — it is an engineered property of the polymer’s ionizable carboxyl groups, which become deprotonated above a material-specific threshold pH, causing the polymer matrix to swell and release its payload.
For a deeper background on the chemical challenges peptides face in the gastrointestinal tract, see our companion article on how oral peptides survive stomach acid: mechanisms and formulation strategies.
Preclinical research employs three principal coating architectures, each with distinct release kinetics and formulation requirements.
In a matrix system, the active peptide is dispersed homogeneously throughout the enteric polymer. Dissolution and diffusion occur simultaneously once the pH threshold is crossed. Release rate depends on polymer density, peptide molecular weight, and intestinal pH. Matrix systems are common in early-stage preclinical work because they are straightforward to manufacture and characterize via standard USP Apparatus 2 (paddle) dissolution testing.
Reservoir systems apply an enteric polymer as a shell around a peptide-containing core. The core may itself be a matrix, a pellet, or a compressed tablet. Upon reaching the dissolution pH, the membrane ruptures or dissolves, providing a burst-type release profile that can be useful for modeling rapid intestinal absorption in rodent pharmacokinetic studies. Multi-unit pellet systems (MUPS) are a reservoir variant that distributes drug across hundreds of enteric-coated pellets, reducing peak concentration variability in in vivo experiments.
Osmotic enteric tablets use a semi-permeable enteric membrane with a laser-drilled orifice. Intestinal fluid enters through the membrane, creating osmotic pressure that pushes the peptide solution through the orifice at a controlled rate independent of local pH fluctuations — important for segments of the intestine where pH can vary between 6.0 and 7.4. These systems are more complex to fabricate but produce highly reproducible zero-order release profiles suited to mechanistic pharmacokinetic modeling.
The choice of enteric polymer determines where in the gastrointestinal tract payload release begins. The table below summarizes the four materials most commonly evaluated in published preclinical oral peptide formulation literature, based on data from USP <711> dissolution testing and supplier technical specifications.
| Material | pH Dissolution Threshold | Release Profile | Primary Research Use |
|---|---|---|---|
| Eudragit L100 (methacrylic acid copolymer) | ≥ 6.0 | Rapid burst at proximal small intestine pH; complete dissolution within 45–60 min at pH 6.8 (USP SGF) | Proximal small intestine targeting; BPC-157, GLP-1 analog, and growth hormone secretagogue preclinical studies |
| HPMC Phthalate (HPMC-P / HP-55) | ≥ 5.5 | Gradual dissolution beginning in distal duodenum; moderate burst | Duodenal absorption window studies; sensitive peptide analogs requiring early intestinal release |
| Cellulose Acetate Phthalate (CAP) | ≥ 6.0 (moisture-sensitive) | Variable burst; more sensitive to humidity during storage, affecting real-world dissolution reproducibility | Historical reference standard in comparative dissolution studies; less common in contemporary formulation research due to moisture instability |
| Shellac (purified lac resin) | ≥ 7.0 | Slow, sustained release; targets terminal ileum and ileocecal junction | Colonic targeting research; gut microbiome interaction studies; delayed-release designs for lower GI peptide delivery models |
Eudragit L100 is the most widely referenced enteric polymer in peer-reviewed oral peptide delivery literature, partly because its dissolution threshold (pH 6.0) corresponds closely to the proximal jejunum where peptide transporter density — including PepT1 — is highest in rodent models (Estudante et al., 2013, European Journal of Pharmaceutics and Biopharmaceutics).
Regulatory and research standards for characterizing enteric formulations are defined in USP <711> (Dissolution) and the FDA’s 2012 guidance on dissolution testing of immediate- and modified-release oral solid dosage forms. The standard two-stage method relevant to enteric coatings proceeds as follows:
For research purposes, additional pH stages (5.5, 6.0, 7.0, 7.4) are often tested sequentially to map the full dissolution profile and identify the precise pH trigger. High-performance liquid chromatography (HPLC) or UV spectrophotometry is used to quantify peptide concentration in dissolution media, with peptide integrity confirmed by mass spectrometry to distinguish intact peptide from degradation fragments.
In vivo correlation (IVIVC) models attempt to link in vitro dissolution data to pharmacokinetic parameters measured in rodent studies. For a species-specific example of how in vitro data relates to bioavailability outcomes, see our analysis of oral BPC-157 bioavailability in preclinical models.
The peptide compounds available through biohacker.team’s research catalog are formulated as research-grade enteric capsules, manufactured to support in vitro and preclinical in vivo experimental protocols. Formulations are encapsulated using Eudragit L100-based enteric systems sized and filled under controlled conditions appropriate for laboratory research supply. Each lot is produced to support dissolution characterization and is not intended for administration to humans or animals outside an approved research framework.
Research institutions sourcing oral peptide enteric formulations for mechanism-of-action studies, absorption window mapping, or comparative dissolution work will find the catalog organized by compound class and release specification.
Standard (immediate-release) capsule shells dissolve within minutes in gastric fluid, exposing the peptide to low pH and pepsin. Enteric-coated capsules use pH-responsive polymer shells that remain intact below pH 5.5–6.0 and dissolve only upon reaching the small intestine. In preclinical dissolution testing, this difference is measured as the percentage of peptide released during the acid stage — ideally less than 10% for a well-formulated enteric system versus nearly complete release for an uncoated capsule.
Eudragit L100 offers superior moisture stability compared to cellulose acetate phthalate (CAP), which is hygroscopic and can develop micro-cracks during storage, leading to premature acid-stage release. Eudragit L100 also has a well-characterized, consistent dissolution threshold (pH 6.0) with lower batch-to-batch variability, making it more suitable for experiments requiring reproducible release profiles across multiple study replicates.
Gastrointestinal pH in rats and mice differs from human values: rat jejunal pH typically ranges from 6.5 to 7.5, and transit times are significantly shorter (cecal arrival in approximately 90–180 minutes versus 3–5 hours in humans). This means that a formulation using a pH 7.0 threshold polymer (e.g., shellac) may not dissolve reliably in a rat model before reaching the cecum. Researchers must account for species-specific pH gradients when selecting enteric polymers for in vivo preclinical protocols.
The USP <711> criterion that no more than 10% of labeled content is released during the 2-hour acid stage is a quality threshold ensuring the enteric barrier is functionally intact under simulated gastric conditions. In practice, well-manufactured enteric capsules typically show less than 2–5% release in the acid stage. Values approaching 10% may indicate coating defects, insufficient coating weight, or polymer degradation and would typically trigger a formulation review before the batch is used in downstream studies.
No. While enteric coating addresses acid-mediated hydrolysis and pepsin degradation, it does not protect against intestinal proteases (trypsin, chymotrypsin, elastase) encountered after coating dissolution. Some peptide analogs also have poor membrane permeability at intestinal pH regardless of coating. Enteric coating is therefore most effective for peptides with reasonable intestinal permeability and moderate resistance to intestinal enzymatic degradation. Formulation strategies combining enteric coating with protease inhibitor co-encapsulation or permeation enhancers are subjects of active preclinical research.
No single in vitro method fully predicts intestinal absorption. The standard two-stage USP dissolution test characterizes coating integrity and release kinetics. Permeability is separately assessed using Caco-2 cell monolayer assays (simulating human intestinal epithelium) or everted gut sac models from rodent intestinal tissue. Combining dissolution data with Caco-2 apparent permeability (Papp) values provides the most informative in vitro dataset for constructing IVIVC models and designing in vivo pharmacokinetic studies.
Research & Preclinical Use Disclaimer: All compounds and formulations described on this site and in this article are intended exclusively for in vitro laboratory research and approved preclinical studies. They are not intended for human or veterinary consumption, self-administration, or any use outside a controlled research environment. Nothing in this article constitutes medical advice, clinical guidance, or a recommendation for use in humans. Researchers are responsible for ensuring compliance with all applicable institutional, regulatory, and legal requirements governing their work.
Each compound available on biohacker.team is verified by our specialist research team through independent third-party HPLC authentication, with batch-level certificates of analysis published openly. Our experts cross-reference purity data with published pharmacology literature to ensure compound integrity.